醋酸氯地孕酮治疗良性前列腺增生的疗效观察

Analysis of effectiveness of chlormadinone acetate in the treatment of patients with benign prostatic hyperplasia

目的探讨醋酸氯地孕酮治疗良性前列腺增生的临床疗效。方法观察32例接受醋酸氯地孕酮(CMA)治疗的良性前列腺增生患者(50mg/d,qd),治疗18周后,对比分析治疗前后前列腺体积、国际前列腺症状评分/生活质量评分(IPSS/QoL)、最大尿流率、勃起功能国际问卷(IIEF-5),并记录出现的不良事件。结果用药18周后,患者前列腺体积、IPSS、PSS-排尿期症状评分、IPSS-储尿期症状评分、生活质量评分、IIEF-5均较治疗前均明显下降(P<0.05);最大尿流率较治疗前均明显上升(P<0.05)。结论醋酸氯地孕酮可较全面地缓解良性前列腺增生患者的症状,有利于患者生活质量的改善。

Objective To explore the effectiveness of chlormadinone acetate in the treatment of patients with benign prostatic hyperplasia.Methods Thirty-two patients with benign prostatic hyperplasia were included in the study.All patients received chlormadinone acetate（50 mg /d） for 18 weeks.The prostate volume,International Prostate Symptom Score /Quality of Life,（IPSS /QoL）,maximum urinary flow rate,international index of erectile function-5（IIEF-5）,and the adverse events were recorded.Results After treatment with chlormadinone acetate,the IPSS,IPSS voiding score,IPSS storage score,QoL,and IIEF-5 significantly decreased in patients（P0.05）.Meanwhile,maximum urinary flow rate significantly increased（P 0.05）.Conclusion The therapy with chlormadinone acetate effectively relieves the symptoms of benign prostatic hyperplasia and improves the quality of life.